Chronic kidney disease in patients with normal eGFR at baseline: results from EuroSIDA
© Ryom et al; licensee BioMed Central Ltd. 2010
Published: 8 November 2010
Chronic kidney disease (CKD) is an emerging co-morbidity among HIV patients. Recent EuroSIDA analyses identified CKD risk factors including hypertension, diabetes, hepatitis C, age>50, low CD4 count, prior AIDS events and cumulative exposure to certain antiretrovirals (ARVs; tenofovir, indinavir atazanavir and probably lopinavir/ritonavir).
We aimed to extend our previous findings by estimating the CKD incidence among patients with normal kidney function at baseline with and without other risk factors, in order to disentangle if ARVs also pose a risk to patients with normal kidney function , and not only to those with pre-existing impairment.
Cockcroft-Gault equation standardised for body surface was used to estimate Glomerular filtration rate (eGFR, ml/min/1,73m2). Patients with baseline eGFR> 90 were included. Baseline was defined as the first eGFR assessment after 01.01.2004. CKD was defined as 2 consecutive eGFR<60 (>3 months apart). Follow-up was from baseline until CKD or last eGFR. Unadjusted incidence rates (IR) are presented per 100 PYFU and stratified by cumulative ARV exposure.
This study of almost 5000 patients and a median follow-up >3 years demonstrates that CKD development from normal kidney function was infrequent. The IR was higher in patients with renal risk factors and those cumulative exposed to the ARVs investigated in unadjusted models. This suggests that ARVs might also pose a risk in patients with normal kidney function. Adjusted analyses were not possible due to low IR. Future studies with substantially larger size and longer follow up are needed to reproduce the findings in adjusted models, determine the role of cumulative exposure to individual ARVs and investigate the clinical implications.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.